| Patricia Ann Howell, MD | |
|
11600 W 2nd Pl, Lakewood, CO 80228-1527 | |
| (720) 321-0000 | |
| Not Available |
| Full Name | Patricia Ann Howell |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 11600 W 2nd Pl, Lakewood, Colorado |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598859399 | NPI | - | NPPES |
| 53308735 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | DR.0037555 (Colorado) | Secondary |
| 207Q00000X | Family Medicine | DR.0037555 (Colorado) | Primary |
| Entity Name | Catholic Health Initiatives Colorado |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356783351 PECOS PAC ID: 8022927342 Enrollment ID: O20031215000462 |
News Archive
BioElectronics Corporation., the maker of inexpensive, disposable drug-free topical pain and healing devices, today announced an agreement with Shanghai Lixiu Medical Devices Co., Ltd. – a subsidiary of Shanghai SuoKang Medical Implants Co., Ltd. - to sell BIEL's RecoveryRx, chronic wound and surgical devices, throughout the People's Republic of China to licensed medical providers.
The 2012 Inserm prizes for medical research will be awarded at a ceremony at the Coll-ge de France on Monday 3 December 2012. This year, the grand prize will be awarded to Philippe Sansonetti in the presence of Marisol Touraine, France's Minister of Social Affairs and Health, Genevi-ve Fioraso, France's Minister of Higher Education and Research, and Professor Andr- Syrota, Chairman and CEO of Inserm.
An innovative therapeutic strategy for reducing the levels of toxic protein fragments associated with Huntington's disease uses a new approach called exon skipping to remove the disease-causing component of the essential protein, huntingtin.
SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care.
Overall, breast cancer rates in the United States have stabilized since the 2000s. But according to the results of a new study led by a researcher from the University of California, Riverside, a subset of women living in the U.S. may be at higher risk for breast cancer than previously observed.
› Verified 7 days ago
| Entity Name | Carepoint Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275516346 PECOS PAC ID: 0547154957 Enrollment ID: O20040209000313 |
News Archive
BioElectronics Corporation., the maker of inexpensive, disposable drug-free topical pain and healing devices, today announced an agreement with Shanghai Lixiu Medical Devices Co., Ltd. – a subsidiary of Shanghai SuoKang Medical Implants Co., Ltd. - to sell BIEL's RecoveryRx, chronic wound and surgical devices, throughout the People's Republic of China to licensed medical providers.
The 2012 Inserm prizes for medical research will be awarded at a ceremony at the Coll-ge de France on Monday 3 December 2012. This year, the grand prize will be awarded to Philippe Sansonetti in the presence of Marisol Touraine, France's Minister of Social Affairs and Health, Genevi-ve Fioraso, France's Minister of Higher Education and Research, and Professor Andr- Syrota, Chairman and CEO of Inserm.
An innovative therapeutic strategy for reducing the levels of toxic protein fragments associated with Huntington's disease uses a new approach called exon skipping to remove the disease-causing component of the essential protein, huntingtin.
SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care.
Overall, breast cancer rates in the United States have stabilized since the 2000s. But according to the results of a new study led by a researcher from the University of California, Riverside, a subset of women living in the U.S. may be at higher risk for breast cancer than previously observed.
› Verified 7 days ago
| Entity Name | Portercare Adventist Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760761928 PECOS PAC ID: 0941110886 Enrollment ID: O20090115000327 |
News Archive
BioElectronics Corporation., the maker of inexpensive, disposable drug-free topical pain and healing devices, today announced an agreement with Shanghai Lixiu Medical Devices Co., Ltd. – a subsidiary of Shanghai SuoKang Medical Implants Co., Ltd. - to sell BIEL's RecoveryRx, chronic wound and surgical devices, throughout the People's Republic of China to licensed medical providers.
The 2012 Inserm prizes for medical research will be awarded at a ceremony at the Coll-ge de France on Monday 3 December 2012. This year, the grand prize will be awarded to Philippe Sansonetti in the presence of Marisol Touraine, France's Minister of Social Affairs and Health, Genevi-ve Fioraso, France's Minister of Higher Education and Research, and Professor Andr- Syrota, Chairman and CEO of Inserm.
An innovative therapeutic strategy for reducing the levels of toxic protein fragments associated with Huntington's disease uses a new approach called exon skipping to remove the disease-causing component of the essential protein, huntingtin.
SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care.
Overall, breast cancer rates in the United States have stabilized since the 2000s. But according to the results of a new study led by a researcher from the University of California, Riverside, a subset of women living in the U.S. may be at higher risk for breast cancer than previously observed.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Patricia Ann Howell, MD 11600 W 2nd Pl, Lakewood, CO 80228-1527 Ph: (720) 321-0000 | Patricia Ann Howell, MD 11600 W 2nd Pl, Lakewood, CO 80228-1527 Ph: (720) 321-0000 |
News Archive
BioElectronics Corporation., the maker of inexpensive, disposable drug-free topical pain and healing devices, today announced an agreement with Shanghai Lixiu Medical Devices Co., Ltd. – a subsidiary of Shanghai SuoKang Medical Implants Co., Ltd. - to sell BIEL's RecoveryRx, chronic wound and surgical devices, throughout the People's Republic of China to licensed medical providers.
The 2012 Inserm prizes for medical research will be awarded at a ceremony at the Coll-ge de France on Monday 3 December 2012. This year, the grand prize will be awarded to Philippe Sansonetti in the presence of Marisol Touraine, France's Minister of Social Affairs and Health, Genevi-ve Fioraso, France's Minister of Higher Education and Research, and Professor Andr- Syrota, Chairman and CEO of Inserm.
An innovative therapeutic strategy for reducing the levels of toxic protein fragments associated with Huntington's disease uses a new approach called exon skipping to remove the disease-causing component of the essential protein, huntingtin.
SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care.
Overall, breast cancer rates in the United States have stabilized since the 2000s. But according to the results of a new study led by a researcher from the University of California, Riverside, a subset of women living in the U.S. may be at higher risk for breast cancer than previously observed.
› Verified 7 days ago
Dr. Kathryn Burkhardt Goeke, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11600 W 2nd Pl, Lakewood, CO 80228 Phone: 720-321-0000 Fax: 720-321-1759 | |
Joshua R Ward, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11600 W 2nd Pl, Lakewood, CO 80228 Phone: 303-731-9782 Fax: 720-321-1759 | |
Aimee Sue Nelson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8585 W 14th Ave, Suite B2, Lakewood, CO 80215 Phone: 303-238-1201 Fax: 303-238-2981 | |
Dr. Kris Alan Johnson, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 155 Van Gordon St, Suite #395, Lakewood, CO 80228 Phone: 303-914-2680 | |
Edward Shuherk, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 12790 W Alameda Pkwy, Lakewood, CO 80228 Phone: 303-403-6350 Fax: 303-403-6372 | |
Alan Schultz, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 165 S Union Blvd Ste 800, Lakewood, CO 80228 Phone: 303-988-2680 Fax: 303-986-8057 | |
Benjamin Charles Schnell, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 255 Union Blvd, 300, Lakewood, CO 80228 Phone: 303-986-9583 |